Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Enliven Therapeutics Inc shares valued at $52,593 were sold by Hohl Benjamin on May 27 ’25. At $16.18 per share, Hohl Benjamin sold 3,250 shares. The insider’s holdings dropped to 23,000 shares worth approximately $0.41 million following the completion of this transaction.
Also, Hohl Benjamin purchased 3,250 shares, netting a total of over 53,300 in proceeds.
Before that, Lyssikatos Joseph P had sold 5,000 shares from its account. In a trade valued at $81,534, the CHIEF SCIENTIFIC OFFICER traded Enliven Therapeutics Inc shares for $16.31 each. Upon closing the transaction, the insider’s holdings decreased to 5,000 shares, worth approximately $17.48 million.
As published in their initiating research note from BTIG Research on December 13, 2024, Enliven Therapeutics Inc [ELVN] has been a Buy and the price target has been revised to $42. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early September. As of June 11, 2024, Robert W. Baird has initiated its “an Outperform” rating for ELVN. Earlier on April 09, 2024, Mizuho initiated its rating. Their recommendation was “a Buy” for ELVN stock.
Analyzing ELVN Stock Performance
During the last five days, there has been a surge of approximately 4.78%. Over the course of the year, Enliven Therapeutics Inc shares have dropped approximately -21.16%. Shares of the company reached a 52-week high of $25.37 on 01/03/25 and a 52-week low of $13.30 on 04/10/25.
Support And Resistance Levels for Enliven Therapeutics Inc (ELVN)
According to the 24-hour chart, there is a support level at 16.60, which, if violated, would cause prices to drop to 15.47. In the upper region, resistance lies at 18.34. The next price resistance is at 18.95. RSI (Relative Strength Index) is 49.36 on the 14-day chart, showing neutral technical sentiment.
